Crescent Biopharma (CBIO) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Oculis (OCS) over the past year, gaining 17.1% versus a loss of 56.4%. Over five years, OCS leads with a -11.8% price change compared with -92.9% for CBIO. Oculis is the larger company by market cap ($533.4 million vs $524.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | OCS |
|---|---|---|
| Share price | $14.12 | $8.66 |
| Market cap | $524.51M | $533.35M |
| 1-day change | +4.67% | +1.88% |
| YTD return | +19.06% | -56.63% |
| 1-year return | +17.08% | -56.42% |
| 5-year return | -92.87% | -11.81% |
| EPS (TTM) | $-7.63 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $34.48 |
| 52-week low | $8.72 | $8.30 |
| Distance from 52-week high | -48.49% | -74.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.09% | +321.36% |
| Average volume | 399.18K | 257.00K |
| Shares outstanding | 37.14M | 61.59M |
| Employees | 69 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed OCS by 73.5 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
CBIO vs OCS FAQ
Which is bigger, Crescent Biopharma or Oculis?
Oculis (OCS) is larger, with a market capitalization of $533.35M compared with $524.51M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or OCS?
CBIO returned +17.08% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.